Oncotype DX and proliferation response to short-term preoperative endocrine therapy for chemotherapy decision in early breast cancer: Biomarker data from the prospective multicenter phase II/III WSG-ADAPT trial.
Oleg Gluz
Honoraria - Genomic Health
Ulrike Nitz
Consultant or Advisory Role - Genomic Health
Honoraria - Genomic Health
Ronald Kates
Consultant or Advisory Role - Celgene (I); Roche (I)
Honoraria - Celgene (I); Novartis (I); Roche (I)
Research Funding - Amgen (I); Celgene (I); Genomic Health (I); Roche (I); Teva (I)
Daniel Hofmann
No relevant relationships to disclose
Sherko Kümmel
No relevant relationships to disclose
Benno Nuding
No relevant relationships to disclose
Claudia Schumacher
No relevant relationships to disclose
Bahriye Aktas
No relevant relationships to disclose
Helmut Forstbauer
No relevant relationships to disclose
Nicolai Maass
No relevant relationships to disclose
Michael Wilhelm Braun
No relevant relationships to disclose
Mahdi Rezai
No relevant relationships to disclose
Manfred Kusche
No relevant relationships to disclose
Albert von der Assen
No relevant relationships to disclose
Steven Shak
Employment or Leadership Position - Genomic Health
Christer Svedman
Employment or Leadership Position - Genomic Health
Rachel Wuerstlein
No relevant relationships to disclose
Nadia Harbeck
Consultant or Advisory Role - Celgene; Roche
Honoraria - Celgene; Novartis; Roche
Research Funding - Amgen; Celgene; Genomic Health; Roche; Teva
Hans Heinrich Kreipe
No relevant relationships to disclose
Matthias Christgen
No relevant relationships to disclose